About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
Videos
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
63 y/o Male With MCL: What Initial Therapy to Choose? What Would Be the Preferred 2L Therapy & Beyond?
By
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
FEATURING
Adam Duvall
,
Peter Riedell
,
Ben Derman
,
Satyajit Kosuri
By
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
FEATURING
Adam Duvall
,
Peter Riedell
,
Ben Derman
,
Satyajit Kosuri
230 views
March 8, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Videos
05:11
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1…
Feat.
B. Derman
21:25
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on Frontline MM: What Is the Optimal Induction Regimen? …
Feat.
B. Derman
11:49
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
35 y/o Male With Newly Diagnosed ALL: What Findings Are Traditionall…
Feat.
A. Duvall,
P. Riedell,
B. Derman,
S. Kosuri
15:12
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
63 y/o Male With MCL: What Initial Therapy to Choose? What Would Be …
Feat.
A. Duvall,
P. Riedell,
B. Derman,
S. Kosuri
17:01
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
Newly Diagnosed MM Case Discussion: Classifying Patient Risk, and Ap…
Feat.
A. Duvall,
P. Riedell,
B. Derman,
S. Kosuri
14:37
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
Expert Analysis of a Primary Myelofibrosis Case: What Tests Could Be…
Feat.
A. Duvall,
P. Riedell,
B. Derman,
S. Kosuri
24:46
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on Non-Malignant Hematology: Mycophenolate for ITP, CTX0…
Feat.
M. Thirman
34:05
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Practice Changing Updates in AML: Maintenance Oral Aza, Lower In…
Feat.
C. DiNardo
30:26
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Advances in Cellular Therapy: Tisa-Cel in R/R B-ALL, Blinatumoma…
Feat.
A. Jakubowiak
27:46
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Highlights on High-Risk MDS in HMA Era: Oral HMAs, BCL2 Inhibiti…
Feat.
O. Odenike
16:45
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
Best of ASH on SCT in Leukemias: Who Should Be Referred Early for AS…
Feat.
S. Kosuri
16:23
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Update on SCT for Myeloid and Lymphoid Leukemias: Apamistamab as…
Feat.
S. Kosuri
17:31
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on SoC in Lymphomas: How Beneficial Are Newly Approved B…
Feat.
P. Riedell
07:31
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Check…
Feat.
P. Riedell
06:44
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on SoC in R/R MCL: How Active Are Novel BTKi & CAR-T…
Feat.
P. Riedell